January 21, 2026 a 11:43 am
AMGN: Fundamental Ratio Analysis - Amgen Inc.
Amgen Inc. (AMGN) is a key player in the biotechnology sector, focusing on developing therapies for serious illnesses. The stock demonstrates strong resilience with a stable performance across various metrics but faces challenges like high debt to equity ratios. Additionally, with its diversified product line, Amgen remains a promising investment, despite the competitive market landscape.
Fundamental Rating
The fundamental analysis of Amgen Inc. reveals a balanced rating, with particular strength in discounted cash flow and return on equity. However, debt to equity remains a concern.
| Category | Score | Visualizer |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return On Equity | 5 | |
| Return On Assets | 4 | |
| Debt To Equity | 1 | |
| Price To Earnings | 2 | |
| Price To Book | 1 |
Historical Rating
The historical scores show consistent performance with significant attributes in DCF and ROE, though with some volatility in overall scores.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-21 | 3 | 5 | 5 | 4 | 1 | 2 | 1 |
| 2026-01-20 | 3 | 5 | 5 | 4 | 1 | 2 | 1 |
Analyst Price Targets
Analyst price targets indicate a potential upward trend, with the median price targeted at $372, suggesting future growth potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $425 | $304 | $372 | $358.89 |
Analyst Sentiment
The analyst sentiment is predominantly positive with a consensus rating of "buy", highlighting strong market confidence.
| Recommendation | Count | Visualizer |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 21 | |
| Hold | 12 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Amgen Inc.'s stock demonstrates a robust fundament with strengths in cash flow and equity returns, positioning it well for potential growth. While the debt to equity ratio is a concern, strong analyst sentiment and a favorable market position highlight potential upside. Investors should consider both external market factors and Amgen's competitive footing in their decisions. Opportunities may arise from new product launches and collaborations, while the high debt is a key challenge to monitor.